NeuBase Therapeutics, Inc. - FORM 10-K - EX-32.1 - SECTION 906 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - January 3, 2019

Attached files

file filename
10-K - ANNUAL REPORT - NeuBase Therapeutics, Inc.ohr-10k_093018.htm
EX-32.2 - SECTION 906 CERTIFICATION OF CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex32-2.htm
EX-31.2 - SECTION 302 CERTIFICATION OF CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex31-2.htm
EX-31.1 - SECTION 302 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex31-1.htm
EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - NeuBase Therapeutics, Inc.ex-23.htm
EX-21 - SUBSIDIARIES OF THE REGISTRANT - NeuBase Therapeutics, Inc.ex-21.htm

 

Ohr Pharmaceutical, Inc. 10-K

 

Exhibit 32.1

Certification of Chief Executive Officer
Pursuant to 18 U.S.C Section 1350,
As Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002

 

Not Filed Pursuant to the Securities Exchange Act of 1934

 

In connection with the Annual Report of Ohr Pharmaceutical, Inc. (the “Company”) on Form 10-K for the fiscal year ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jason Slakter, Chief Executive Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: January 3, 2019

 

/s/ Jason Slakter
Jason Slakter, Chief Executive Officer
(Principal Executive Officer)

 


 

 

NeuBase Therapeutics, Inc. Reports